myelodysplastic syndromes (MDS) | Page 6 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Aplastic Anemia, MDS, and PNH Virtual Support Group

Event Date: 
Sat, 05/28/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator

PURPOSE:
Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.”

Sabatolimab

Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukemic cells. Sabatolimab also binds to TIM-3 on leukemic cells, potentially impeding self-renewal of LSCs via inhibition of TIM3-galectin-9.

Find Out More:

Aplastic Anemia, MDS, and PNH Virtual Support Group

Event Date: 
Sat, 04/23/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Share with addtoany.com.